ARCHIVES

NCI To Proceed With Guidelines Unless Board Strongly Disagree

This article is from The Cancer Letter archive.

Vol. 06 No. 19 | May 9, 1980

Download PDF Visit The Full Archive

Related Articles

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

In Brief: Newell Tells Advisory Committee It Isn’t a Lobbying Group, “Accept What We Give You”

April 8, 1977

NDA For MeCCNU Turned Down By Oncologic Drugs Advisory Committee

September 3, 1976

Has To Plan International Meeting On Threat If DNA Biohazards

September 13, 1974

Pancreatic Cancer Pain Reduction Concept Approved

May 23, 1986